AI-generated summary
This protocol describes a planned randomised, placebo-controlled trial of whole-body photobiomodulation in 44 people with fibromyalgia, with outcomes including pain, function, tissue quality and psychological factors. The authors have not yet reported results; they state the trial will investigate whether the treatment is effective and will include follow-up at 3 and 6 months.
- Participants
- 44
- Who or what was studied
- Adults with fibromyalgia syndrome recruited in a private care practice (planned, not yet enrolled)
- Wavelengths
- 660, 850 nm
- Limits stated in the abstract
- This is a study protocol without results, so no findings about effectiveness are reported.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Energy density (fluence)
- 25.2 J/cm2
- Power
- 967 W
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Fibromyalgia, Placebo-controlled, Trial registration, Primary outcome, Near-infrared, Inflammation, Fluence. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.